Trial Profile
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs AEG 40826 (Primary)
- Indications Lymphoid leukaemia
- Focus Adverse reactions
- Sponsors Human Genome Sciences
- 09 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Nov 2009 New trial record